Few of the newfangled consumer genetic testing products have had greater commercial success and visibility than Exact Science’s Cologuard colorectal cancer screening test. But a troubling new government report casting doubt on the product’s effectiveness might have burst the Cologuard bubble, at least for now. The Growth of Cologuard Launched in 2014, Cologuard is the first stool multi-target stool DNA test (mtSDNA) for colorectal cancer screening. It has been ordered by nearly174,000, including 142,000 primary care physicians, with 900 new doctors joining the list of orderers each week. According to Madison, Wisconsin-based Exact Science’s figures, Cologuard rakes in average revenues of $479 per test at an average cost of $123. The test, which is covered by Medicare, now commands 6% of the total U.S. colorectal cancer testing market. Adding to the buzz is the recent announcement of Exact’s impending $2.8 billion acquisition of Genomic Health, producer of the equally dynamic Oncotype DX consumer genetic screening tests for breast and prostate cancer. Collectively, Cologuard and the two Oncotype DX products represent approximately 40% of all solid tumor incidence. Exact’s Chairman and CEO Kevin Conroy touted the Genomic Health acquisition as “a pivotal step toward building the leading cancer diagnostics company in […]